Home  |  Contact

UniProtKB/Swiss-Prot Q03252: Variant p.His157Tyr

Lamin-B2
Gene: LMNB2
Chromosomal location: 19p13.3
Variant information

Variant position:  157
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  Disease [Disclaimer]
The variants are classified into three categories: Disease, Polymorphism and Unclassified.
  • Disease: Variants implicated in disease according to literature reports.
  • Polymorphism: Variants not reported to be implicated in disease.
  • Unclassified: Variants with uncertain implication in disease according to literature reports. Evidence against or in favor of a pathogenic role is limited and/or conflicting.

Residue change:  From Histidine (H) to Tyrosine (Y) at position 157 (H157Y, p.His157Tyr).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from medium size and polar (H) to large size and aromatic (Y)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  2
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Involvement in disease:  Epilepsy, progressive myoclonic 9 (EPM9) [MIM:616540]: An autosomal recessive form of progressive myoclonic epilepsy, a rare disease initially responsive to antiepileptic drugs which over time becomes refractory and can be associated with cognitive decline. EPM9 features include myoclonus, tonic-clonic seizures, ataxia, and psychomotor development. {ECO:0000269|PubMed:25954030}. Note=The disease may be caused by mutations affecting the gene represented in this entry.
The name and a short description of the disease associated with the variant. For more information about the disease, the user can refer to OMIM, following the link provided after the disease acronym.

Variant description:  In EPM9; disrupts fibrillar formation.
Any additional useful information about the variant.

Other resources:  
Links to websites of interest for the variant.



Sequence information

Variant position:  157
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  620
The length of the canonical sequence.

Location on the sequence:   KREGELTVAQGRVKDLESLF  H RSEVELAAALSDKRGLESDV
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         KREGELTVAQGRVKDLESLFHRSEVELAAALSDKRGLESDV

Mouse                         KREGELTVAQGRVKDLESLFHRSEAELATALSDKQGLETEV

Chicken                       KKDADLSVAQGRIKDLEVLFHRSEAELNTVLNEKRSLEAEV

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 1 – 617 Lamin-B2
Domain 46 – 402 IF rod
Region 96 – 229 Coil 1B


Literature citations

Mutation of the nuclear lamin gene LMNB2 in progressive myoclonus epilepsy with early ataxia.
Damiano J.A.; Afawi Z.; Bahlo M.; Mauermann M.; Misk A.; Arsov T.; Oliver K.L.; Dahl H.H.; Shearer A.E.; Smith R.J.; Hall N.E.; Mahmood K.; Leventer R.J.; Scheffer I.E.; Muona M.; Lehesjoki A.E.; Korczyn A.D.; Herrmann H.; Berkovic S.F.; Hildebrand M.S.;
Hum. Mol. Genet. 24:4483-4490(2015)
Cited for: VARIANT EPM9 TYR-157; CHARACTERIZATION OF VARIANT EPM9 TYR-157;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.